Log In

 

Company Name : Ferring Pharmaceuticals

Thursday, February 15, 2018 4:13PM IST (10:43AM GMT)

(BW)(FERRING-PHARMACEUTICALS)

Ferring Announces 30 Million CHF Investment in New Biotech Centre in Switzerland


Ferring expands its capabilities in biologics through a new biotech centre, which will be installed at its global headquarters and manufacturing site in St Prex, Switzerland; Ferring Biotech Centre will incorporate discovery and development capabilities for monoclonal antibodies as well as manufacturing capabilities for biologics; In addition to new biologics in reproductive medicine and women’s health, fertility treatment Rekovelle® (follitropin delta) will also be manufactured at the new centre


Saint-Prex, Switzerland

Ferring Pharmaceuticals announced that it is expanding its capabilities in biologics through a new biotech centre which will be installed at the company’s existing headquarters and manufacturing site in Saint-Prex, Switzerland.

 

Over the next three years, Ferring will invest approximately 30 million CHF in the new Ferring Biotech Centre, which will incorporate discovery and development capabilities for monoclonal antibodies as well as biologics manufacturing capabilities.

 

“Ferring is committed to investing in innovative technology platforms to create new solutions for patients in our core areas of reproductive medicine and women’s health, gastroenterology and urology,” said Michel Pettigrew, President of the Executive Board and Chief Operating Officer, Ferring Pharmaceuticals. “This significant investment in state-of-the art manufacturing and development technologies fits our strategy to address unmet patient needs in these areas, and will open up additional opportunities for Ferring to help people live better lives.”

 

In addition to the discovery, development and manufacture of new biologics, the active pharmaceutical ingredient (API) for Rekovelle® (follitropin delta), Ferring’s latest fertility treatment, will also be manufactured at the new Ferring Biotech Centre.

 

Earlier this year, Ferring announced a worldwide license agreement with Ligand Pharmaceuticals to use Ligand’s OmniAb platform® to discover new human monoclonal antibodies and accelerate development solutions for unmet patient needs in reproductive medicine and women’s health, urology and gastroenterology. Together, these investments significantly expand Ferring’s growing capabilities in biologics to create innovative solutions for patients.

 

- Ends -

 

About Ferring Pharmaceuticals:

 

Ferring Pharmaceuticals is a research-driven, speciality biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative and personalised healthcare solutions to help mothers and babies, from conception to birth. Founded in 1950, Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

 

Learn more at www.ferring.com and @Ferring, or connect with us on Facebook, Instagram and LinkedIn.

 

 

 

 


Click here for Media Contact Details
CONTACTS :

Ferring Corporate Communications Team:
Lindsey Rodger
Senior Manager, Corporate Communications
+41 58 451 4023 (direct)
+41 79 191 0486 (mobile)
lindsey.rodger@ferring.com
or
Bhavin Vaid
Head of Corporate Communications
+41 58 301 0952 (direct)
+41 79 191 0632 (mobile)
bhavin.vaid@ferring.com


More News from Ferring Pharmaceuticals

30/08/2018 6:45PM

Ferring and Celmatix Launch Ambitious Genomics Collaboration to Advance Care in Reproductive Medicine and Women’s Health

Research collaboration aims to uncover new insights into ovarian biology and accelerate the development of personalized interventions in reproductive medicine and women’s health Research aims to explore ...

02/07/2018 2:25PM

New Analysis of Rekovelle® Data Further Supports Use of AMH to Personalise Fertility Treatment

Rekovelle’s unique dosing algorithm, which is based on a woman’s anti-Müllerian hormone (AMH) level and body weight, is designed for predictable ovarian response New analysis shows that natural ...

28/06/2018 3:59PM

Ferring’s Heat-Stable Carbetocin Could Save Thousands of Women’s Lives by Preventing Excessive Bleeding after Childbirth

New data show heat-stable carbetocin is as effective as oxytocin, the current standard of care, in preventing excessive bleeding (postpartum haemorrhage (PPH)) following vaginal birth1 Results from the largest ...

Similar News

20/09/2018 5:08PM

5 Benefits of Bajaj Finserv Personal Loan for Doctors

While most doctors are pressed for time, the process of being financed for various life goals should be quick and convenient. Bajaj Finserv’s Personal Loan for Doctors is designed to make money easily accessible without ...

No Image

20/09/2018 2:30PM

Herbalife Nutrition India Signs on Table Tennis Sensation Manika Batra as Its Sponsored Athlete

Herbalife Nutrition today announced its association with Table Tennis star Manika Batra.